Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

Overview

Journal Am J Clin Dermatol

Specialty Dermatology

Date 2019 Sep 8

PMID 31493163

Citations 12

Authors

Mark G Lebwohl

Andrew Blauvelt

Alan Menter

Kim A Papp

Scott Guenthner

Radhakrishnan Pillai

Robert J Israel

Abby Jacobson

Affiliations

Soon will be listed here.

Abstract

Background: Chronic inflammatory diseases such as psoriasis require treatment options that maintain efficacy and tolerability during extended treatment.

Objective: The aim of the study was to assess the long-term efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.

Methods: Patients who completed a 12-week, phase II, dose-ranging clinical trial received brodalumab 210 mg every 2 weeks in an open-label extension study. Efficacy was assessed by static physician's global assessment (sPGA) and psoriasis area and severity index (PASI). Quality of life, assessed by dermatology life quality index (DLQI), and safety were also evaluated.

Results: Overall, 181 patients received brodalumab for a median of 264 weeks. Brodalumab treatment resulted in rapid improvements in sPGA, PASI, and DLQI that were maintained through week 264. Achieving PASI 90 to < 100 or PASI 100 at weeks 12, 240, and 264 was associated with greater likelihood for DLQI 0 or 1 compared with achieving PASI 75 to < 90. Over 5 years, one adverse event of suicidal ideation was reported, no suicides occurred, and no new safety signals emerged.

Conclusions: Brodalumab demonstrated skin clearance and improved quality of life, with an acceptable safety profile, throughout 5 years of treatment. CLINICALTRIALS.

Gov Identifier: NCT01101100.

Citing Articles

Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study.

Elzubeir A, High J, Hammond M, Shepstone L, Pond M, Walmsley M BMJ Open Gastroenterol. 2025; 12(1).

PMID: 40032516 PMC: 11877274. DOI: 10.1136/bmjgast-2024-001596.

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA).

Reich K, Bianchi L, Khemis A, Maul J, Tsianakas A, Schempp C Dermatol Ther (Heidelb). 2024; 14(2):453-468.

PMID: 38300408 PMC: 10891028. DOI: 10.1007/s13555-023-01092-x.

Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis.

Krzysztofik M, Brzewski P, Cuber P, Kacprzyk A, Kulbat A, Richter K Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38276003 PMC: 10820691. DOI: 10.3390/ph17010014.

Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

Wu S, Xu Y, Yang L, Guo L, Jiang X Front Immunol. 2023; 14:1294416.

PMID: 38106423 PMC: 10721978. DOI: 10.3389/fimmu.2023.1294416.

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.

Ruggiero A, Portarapillo A, Megna M, Patruno C, Napolitano M Pediatric Health Med Ther. 2023; 14:435-451.

PMID: 38024562 PMC: 10656860. DOI: 10.2147/PHMT.S389108.

References

Strober B, Karki C, Mason M, Guo N, Holmgren S, Greenberg J . Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2017; 78(2):323-332. DOI: 10.1016/j.jaad.2017.10.012. View

Papp K, Leonardi C, Menter A, Ortonne J, Krueger J, Kricorian G . Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366(13):1181-9. DOI: 10.1056/NEJMoa1109017. View

Lebwohl M, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley R . Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014; 70(5):871-81.e1-30. DOI: 10.1016/j.jaad.2013.12.018. View

Nakagawa H, Niiro H, Ootaki K . Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2015; 81(1):44-52. DOI: 10.1016/j.jdermsci.2015.10.009. View

Iskandar I, Warren R, Lunt M, Mason K, Evans I, Mcelhone K . Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2017; 138(4):775-784. PMC: 5869053. DOI: 10.1016/j.jid.2017.09.044. View

Armstrong A, Gordon K, Menter M, Wu J . The Evolving Landscape of Psoriasis Treatment. Semin Cutan Med Surg. 2018; 37(2S):S39-S43. DOI: 10.12788/j.sder.2018.009. View

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C . Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017; 12:CD011535. PMC: 6486272. DOI: 10.1002/14651858.CD011535.pub2. View

Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson A . Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2019; 82(2):352-359. DOI: 10.1016/j.jaad.2019.05.095. View

Papp K, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C . A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016; 175(2):273-86. DOI: 10.1111/bjd.14493. View

10.

Umezawa Y, Nakagawa H, Niiro H, Ootaki K . Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2016; 30(11):1957-1960. DOI: 10.1111/jdv.13785. View

11.

Timotijevic Z, Majcan P, Trajkovic G, Relic M, Novakovic T, Mirkovic M . The Impact of Changes in Psoriasis Area and Severity Index by Body Region on Quality of Life in Patients with Psoriasis. Acta Dermatovenerol Croat. 2017; 25(3):215-222. View

12.

Parisi R, Symmons D, Griffiths C, Ashcroft D . Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2012; 133(2):377-85. DOI: 10.1038/jid.2012.339. View

13.

Mason K, Barker J, Smith C, Hampton P, Lunt M, Mcelhone K . Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatol. 2018; 154(5):581-588. PMC: 5876819. DOI: 10.1001/jamadermatol.2018.0183. View

14.

Menter A, Papp K, Gooderham M, Pariser D, Augustin M, Kerdel F . Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016; 30(7):1148-58. PMC: 5071685. DOI: 10.1111/jdv.13611. View

15.

Warren R, Smith C, Yiu Z, Ashcroft D, Barker J, Burden A . Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015; 135(11):2632-2640. DOI: 10.1038/jid.2015.208. View

16.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L . Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015; 373(14):1318-28. DOI: 10.1056/NEJMoa1503824. View

17.

Lebwohl M, Papp K, Marangell L, Koo J, Blauvelt A, Gooderham M . Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol. 2017; 78(1):81-89.e5. DOI: 10.1016/j.jaad.2017.08.024. View

18.

Abrouk M, Nakamura M, Zhu T, Farahnik B, Koo J, Bhutani T . The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. J Dermatolog Treat. 2017; 28(6):488-491. DOI: 10.1080/09546634.2016.1278198. View

19.

Feldman S, Goffe B, Rice G, Mitchell M, Kaur M, Robertson D . The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. Am Health Drug Benefits. 2017; 9(9):504-513. PMC: 5394561. View

20.

Kaushik S, Lebwohl M . Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol. 2018; 80(1):43-53. DOI: 10.1016/j.jaad.2018.06.056. View